|
 |
Centres Netherlands |
| Prof. Paul-Peter Tak | |
| Personal | Paul-Peter Tak is Director of the Division of Clinical Immunology & Rheumatology at AMC/University of Amsterdam, Division of Clinical Immunology & Rheumatology, The Netherlands. His department trains 2 new fellows in rheumatology per year; 12 research physicians work on a PhD program, each staying 4 years; 2-4 international fellows per year are being trained in rheumatology and translational research. The Division of Clinical Immunology & Rheumatology offers basic and translational research fellowships combined with AMC’s Graduate School Teaching Program. These training fellowships will equip a talented young clinician to compete and contribute effectively in the translational medicine field. Also, there is a special fellowship supported by AMC aimed at attracting outstanding young, internationally recognised medical and biomedical scientists who are able to set up their own research group. |
| Interests |
Professor Tak’s clinical interests focus on Arthritis (Pre-arthritis, early arthritis, undifferentiated arthritis, rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), cardiovascular disease in autoimmune disease. He sees the whole field of clinical immunology and rheumatotology with a focus on inflammatory and autoimmune disease, including arthritis, vasculitis, SLE, polymyositis, relapsing polychondritis, Sjogren’s syndrome and systemic sclerosis. The research interests include signal transduction pathways and the pathogenesis of synovial inflammation in rheumatoid and spondyloarthritis, and the development and evaluation of immunotherapies and gene therapy for these conditions. Within the department research is performed at three different tiers: clinical studies, animal studies and in vitro studies. |
| Research Projects |
1. Pathogenetic studies on synovial inflammation in RA, PsA, and AS |
| Recent Publications |
Thurlings RM, Vos K, Wijbrandts CA, Zwinderman A, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008 Jul;67(7):917-25. Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP. Rheumatoid Arthritis Synovium Contains Two Subsets of CD83-DC-LAMP- Dendritic Cells with Distinct Cytokine Profiles. Am J Pathol. 2008 Apr;172(4):940-50. Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh Weerman MA, Smeets TJ, Vervoordeldonk MJ, Baeten D, Tak PP. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum. 2008 Nov;58(11):3330-9. van Maanen MA, Lebre MC, van der Poll T, Larosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009 Jan;60(1):114-22. Maanen MA, Stoof SP, Zanden EP, Jonge WJ, Janssen RA, Fischer DF, Vandeghinste N, Brys R, Vervoordeldonk MJ, Tak PP. The alpha7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: A possible role for a key neurotransmitter in synovial inflammation. Arthritis Rheum. 2009 Apr 29;60(5):1272-1281 |
| More Information |
www.amc.nl/index.cfm?sid=525 and www.arthrogen.nl |
| close window | print page |